Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Change in Acquisitions & Divestments (2024 - 2025)

Prelude Therapeutics' Change in Acquisitions & Divestments history spans 2 years, with the latest figure at $6.4 million for Q4 2025.

  • For Q4 2025, Change in Acquisitions & Divestments fell 78.3% year-over-year to $6.4 million; the TTM value through Dec 2025 reached $154.4 million, up 7.48%, while the annual FY2025 figure was $154.4 million, 7.48% up from the prior year.
  • Change in Acquisitions & Divestments for Q4 2025 was $6.4 million at Prelude Therapeutics, down from $40.1 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $71.7 million in Q1 2025 and bottomed at $6.4 million in Q4 2025.